IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

REVIEW ON: BILAYER TABLET USING IN HYPERTENSION & DIABETICS

1Soham galgunde, 2Prof. Nitin Neharkar, 3Pranjal Gaikwad, 4Sahil Dhavale

1B Pharm, 2M Pharm, 3B Pharm, 4B Pharm

1SPPU

ABSTRACT:

Bi-layer tablet is another period for winning the improvement of controlled discharge plan alongside different elements to give fruitful drug conveyance. Bi-layer tablets can be an urgent choice to stay away from substance contrary qualities between dynamic drug fixings (APIs) by actual detachment and to work with the improvement of various medication discharge profiles. Bi-layer tablet is suitable for sequential delivery of two medications in the blend and furthermore for supported arrival of tablet in which one layer is for sure-fire discharge as a stacking portion and the second layer is the upkeep portion. producing, different tablet presses utilized, quality and GMP necessities for their creation different procedures utilized for bi-layer tableting, and late advancements in the field of bi-layer innovation.

KEYWORDS: Bi-layer tablet, Bilayer tablet manufacturing, Diabetic Mellitus.

INTRODUCTION:

Diabetes mellitus is taken from the Greek word diabetes, importance siphon - to go through and the Latin word mellitus meaning sweet. A survey of the set of experiences shows that the expression "diabetes" was first utilized by Apollonius of Memphis around 250 to 300 BC. In 1922 Banting, Best and Collip cleansed the chemical insulin from the pancreas of cows at the College of Toronto, prompting the accessibility of a powerful treatment for diabetes in 1922. Sadly, even today, diabetes is quite possibly of the most well-known ongoing sickness in the nation and around the world. In the US, it stays as the seventh driving reason for death.

Classification of DM

The WHO Expert Committee divided DM into four categories based on age of onset infantile or childhood diabetics (0-14 years). Young diabetics (15-24 years), adult diabetics (25-64 years) and elderly diabetics (above 64 years)

DM was mainly divided into two classes insulin IDDM (type-1) and NIDDM (type2) but type 1 and type 2 were removed in the updated version. The WHO reused type 1 and type 2 in 1999 for DM classification.

Type 1 DM (TIDM)

Most of the beta cells are damaged and this process is autoimmune although the details of this have not yet been established. It can also be triggered by viral infection, although non-infectious factors may also be involved in the initiating mechanism". From this it is revealed that environmental insult is also involved.

T2DM

Although T2DM is more frequent than TIDM and more frequently exhibits familial aggregation. In the first phase, the plasma glucose remains normal despite demonstrable insulin resistance, because insulin levels are elevated. In the second phase, insulin resistance tends to worsen, so that postprandial hyperglycemia develops despite elevated insulin concentrations. In the third phase, insulin resistance does not change, but declining insulin secretion causes fasting hyperglycemia and overt DM."

Etiology:

In the islets of Langerhans in the pancreas, there are two fundamental subclasses of endocrine cells: insulin-creating beta cells and glucagon discharging alpha cells. On account of DM, insulin is either missing or potentially has weakened activity (insulin obstruction), and in this way prompts hyperglycemia.

T1DM is described by the obliteration of beta cells in the pancreas, commonly optional to an immune system process. The outcome is the outright annihilation of beta cells, and significantly, insulin is missing or very low.

T2DM includes a more treacherous beginning where an unevenness between insulin levels and insulin responsiveness causes a practical shortfall of insulin.

Polymorphisms have been known to impact the gamble for T1DM, including significant histocompatibility complex (MHC) and human leukocyte antigen (HLA). [1]

T2DM includes a more complicated interchange among hereditary qualities and way of life. There is obvious proof recommending that T2DM is has a more grounded inherited profile when contrasted with T1DM. Most of patients with the sickness have somewhere around one parent with T2DM. [2]

Monozygotic twins with one impacted twin have a 90% probability of the other twin creating T2DM in his/her lifetime.[3] Roughly 50 polymorphisms to date have been depicted to add to the gamble or security for T2DM.A far reaching affiliation study (GWAS) found hereditary loci for record factor 7-like 2 quality (TCF7L2), which expands the gamble for T2DM.[4][5] Different loci that have suggestions in the improvement of T2DM incorporate NOTCH2, JAZF1, KCNQ1, and WFS1.[6][7]

A few qualities have suggestions in this sickness, including transformations to hepatocyte atomic variable 1-alpha (HNF1A) and the glucokinase (GCK) quality, which happens in 52 to 65 and 15 to 32 percent of MODY cases, respectively.[8][9] The hereditary qualities of this illness are as yet muddled as certain patients have changes however never foster the illness, and others will foster clinical side effects of MODY yet have no recognizable change.

Extreme proinsulin is likewise remembered to assume a part in gestational diabetes, and some propose that proinsulin may prompt beta-cell stress. Others accept that high centralizations of chemicals like progesterone, cortisol, and estrogen might influence beta-cell capability and fringe insulin sensitivity.[10]

Pathophysiology

A patient with DM has the potential for Hyperglycemia. Hyperglycemia alone can hinder pancreatic beta-cell capability and adds to impeded insulin emission. Considerably, there is an endless loop of hyperglycemia prompting a weakened metabolic state. Blood glucose levels over 180 mg/dL are frequently considered hyperglycaemic in this specific circumstance, however as a result of the range of systems, there is no unmistakable limit. Patients experience osmotic diuresis because of immersion of the glucose carriers in the nephron at higher blood glucose levels. Albeit the impact is variable, serum glucose levels over 250 mg/dL are probably going to cause side effects of polyuria and polydipsia. Persistent hyperglycemia likewise causes non enzymatic glycation of proteins and lipids. The degree of this is quantifiable by means of the glycation haemoglobin (HbA1c) test. Glycation prompts harm in little veins in the retina, kidney, and fringe nerves. Higher glucose levels rush the cycle.

Treatment/Management

The physiology and treatment of diabetes are complicated and require a huge number of intercessions for effective sickness the board. Patients have improved results in the event that they can deal with their eating regimen, work-out routinely, and freely screen glucose.[11] Long lasting treatment is much of the time important to forestall undesirable confusions.

Insulin organization through day-to-day infusions, or an insulin siphon, is the backbone of treatment. alpha-glucosidase inhibitors, thiazolidinediones, glucagonlike-peptide-1 agonist, dipeptidyl peptidase IV inhibitors (DPP-4), Prescribed for people have been lethargic to different medicines and who have huge comorbidities.[12]
The ADA likewise suggests customary pulse evaluating for diabetics, with the objective being 130 mmHg systolic circulatory strain and 85 mmHg diastolic blood pressure.[13]

Differential Diagnosis

Notwithstanding T1DM, T2DM, and MODY, any issue that harms the pancreas can bring about DM. There are a few sicknesses of the exocrine pancreas, including:[14]

• Cystic fibrosis

• Genetic hemochromatosis

• Pancreatic disease

• Hormonal conditions that can prompt impeded insulin emission include:

• Pheochromocytoma

• Acromegaly

Drug-prompted insulin opposition is likewise in the differential of traditional diabetes. These medications include:

• Phenytoin

• Glucocorticoids

• Estrogen

Different illnesses in the differential of diabetes mellitus include:

• Gestational diabetes [10]

• Thyroid problems

HYPERTENSION:

Hypertension (HTN or HT), otherwise called hypertension (HBP), is a drawn out ailment where the circulatory strain in the supply routes is perseveringly elevated. Hypertension generally doesn't cause symptoms. [15] Long haul hypertension, notwithstanding, is a significant gamble factor for stroke, coronary conduit illness, cardiovascular breakdown, atrial fibrillation, fringe blood vessel sickness, vision misfortune, constant kidney sickness, and dementia. [16] [17]. Hypertension is a significant reason for sudden passing worldwide.

Around 90-95% of cases are essential, characterized as hypertension because of vague way of life and hereditary factors. [19] [20] The excess 5-10% of cases are arranged as optional hypertension, characterized as hypertension because of a recognizable reason.

For most grown-ups, typical pulse very still is inside the scope of 100-130 millimetres mercury (mmHg) systolic and 60-80 mmHg diastolic.[21][27] For most grown-ups, hypertension is available in the event that

the resting pulse is perseveringly at or over 130/80 or 140/90 mmHg.[19][21] Various numbers apply to children.[28] [24]

Way of life changes incorporate weight reduction, actual activity, diminished salt admission, decreasing liquor consumption, and a sound diet.[19] In the event that way of life changes are not adequate, then pulse meds are used.[22] The treatment of decently high blood vessel circulatory strain (characterized as >160/100 mmHg) with prescriptions is related with a superior life expectancy.[29] [30][31] and others finding hazy benefit.[32][33][34] In 2010 hypertension was accepted to have been a component in 18% of all passings (9.4 million globally).[23]

Classification in adults

Classification in adults (Persons with systolic and diastolic in different categories are assigned to the higher category.[21]

Category	**Systolic, mmHg**	**Diastolic, mmHg**
Hypotension	< 90	< 60
Normal	90–119[21] 90–129[89]	60–79[21] 60–84[89]
Prehypertension (high normal, elevated41])	120–129[21] 130–139[89][90]	60–79[21] 85–89[89][90]
Stage 1 hypertension	130–139[21] 140–159[89]	80–89[21] 90–99[89]
Stage 2 hypertension	>140[21] 160–179[89]	>90[21] 100–109[89]
Hypertensive crises	≥ 180[21]	≥ 120[21]
Isolated systolic hypertension	≥ 140[21]	< 90[21]
Isolated diastolic hypertension[91][92]	< 140	≥ 90

In individuals matured 18 years or more established hypertension is characterized as either a systolic or a diastolic circulatory strain estimation reliably higher than an acknowledged typical worth.[19][21]Different edges are utilized (135 mmHg systolic or 85 mmHg diastolic) in the event that estimations are gotten from 24-hour walking or home monitoring.[75] the term prehypertension for pulse in the reach 120-139 mmHg systolic or 80-89 mmHg diastolic, while European Culture of Hypertension Rules (2007)[76] and English Hypertension Society (BHS) IV (2004)[77]BHS IV (2004)[77] moreover characterize a third stage (stage III hypertension) for individuals with systolic pulse surpassing 179 mmHg or a diastolic tension north of 109 mmHg. Hypertension is delegated "safe" in the event that drugs don't lessen circulatory strain to typical levels.[35] In November 2017, the American Heart Affiliation and American School of Cardiology distributed a joint rule which refreshes the suggestions of the JNC7 report.[78] The 2020 Global Society of Hypertension rules characterize hypertension in view of office pulse ≥140/90 mmHg or home observing pulse ≥135/85 mmHg, or 24-hour wandering pulse normal ≥130/80 mmHg (daytime normal ≥135/85 mmHg or evening normal BP ≥120/70 mmHg).[79]



Fig.1.1: Determinants of mean arterial pressure



Fig.1.2: Illustration depicting the effects of high blood pressure

In the vast majority with laid out fundamental hypertension, expanded protection from blood stream (complete fringe obstruction) represents the high tension while cardiovascular result remains normal.[36] There is proof that a few more youthful individuals with prehypertension or 'marginal hypertension' have high heart yield, named hyperkinetic fringe hypertension.[37] Whether this example is common surprisingly who at last foster hypertension is disputed.[38] The expanded fringe obstruction in laid out hypertension is basically owing to underlying restricting of little conduits and arterioles,[39] albeit a decrease in the number or thickness of vessels may likewise contribute.[40]

It isn't certain whether vasoconstriction of arteriolar veins assumes a part in hypertension.[41] Hypertension is likewise connected with diminished fringe venous compliance.[42] which might increment venous return, increment heart preload and, at last, cause diastolic brokenness.

Numerous systems have been proposed to represent the ascent in fringe opposition in hypertension. Most proof embroils either aggravations in the kidneys' salt and water taking care of [43] or irregularities of the thoughtful apprehensive system.[44] These components are not fundamentally unrelated and almost certainly, both add somewhat in many instances of fundamental hypertension. It has likewise been proposed that endothelial brokenness and vascular irritation may likewise add to expanded fringe obstruction and vascular harm in hypertension.[45][46] Interleukin 17 has gathered interest for its job in expanding the creation of a few other resistant framework substance signals remembered to be engaged with hypertension, for example, growth corruption factor alpha, interleukin 1, interleukin 6, and interleukin 8.[47]

Diagnosis

Hypertension is analyzed based on a relentlessly high resting pulse. The American Heart Affiliation (AHA) suggests something like three laying estimations on no less than two separate medical services visits.[48] The UK Public Foundation for Wellbeing and Care Greatness prescribes wandering pulse observing to affirm the finding of hypertension on the off chance that a centre circulatory strain is 140/90 mmHg or higher.[49]

Prevention

A large part of the infection weight of hypertension is capable by individuals who are not marked as hypertensive. proposed way of life changes reliable with those framed by the US Public High BP Training Project in 2002[50] for the essential counteraction of hypertension:

• keep up with typical body weight for grown-ups (for example weight list 20-25 kg/m2)

• decrease dietary sodium admission to <100 mmol/day (<6 g of sodium chloride or <2.4 g of sodium each day)

• consume an eating routine wealthy in products of the soil (for example something like five parts each day);

• Stress reduction

• contemplation

• steaming showers

• yoga

• continuing long walks

There is impressive proof that decreasing dietary salt admission brings down pulse, however whether this converts into a decrease in mortality and cardiovascular sickness remains uncertain.[51]

Treatment

Generally, the treatment for what was known as the "hard heartbeat sickness" comprised in decreasing the amount of blood by blood draining or the use of leeches. [52] [53]

A few different specialists were created after WWII, the most well-known and sensibly compelling of which were tetramethylammonium chloride, hexamethonium, hydralazine, and reserpine. [54] Consequently, beta blockers, calcium channel blockers, angiotensin changing over compound (ACE) inhibitors, angiotensin receptor blockers, and renin inhibitors were created as antihypertensive agents.[53]

BILAYER TABLET [55][56]

In the last decade, interest in developing a combination of two or more Active Pharmaceutical An ingredient (API) in a single dosage form (bi-layer tablet) has increased in the pharmaceutical industry, promoting patient convenience and compliance. Bi-layer tablets can be a primary option to avoid chemical incompatibilities between APIS by physical separation, and to enable the development of different drug release profiles (immediate release with extended release).



Fig.1.3: Bilayer tablet

NEED OF BILAYER TABLETS [56]

1. For the administration of fixed dose combinations of different APIs, prolong the drug product life cycle, buccal/mucoadhesive delivery systems; fabricate novel drug delivery systems such as chewing device and floating tablets for gastro-retentive drug delivery.

2. Controlling the delivery rate of either single or two different active pharmaceutical ingredient(s)

3. To modify the total surface area available for API layer either by sandwiching with one or two in active layers in order to achieve swellable/erodible barriers for modified release.

4. To separate incompatible Active pharmaceutical ingredient (APIs) from each other, to control the release of API from one layer by utilizing the functional property of the other layer.

ADVANTAGES OF THE BILAYER TABLET DOSAGE FORM [56]

1. Bi-layer execution with optional single-layer conversion kit.

2. Cost is lower compared to all other oral dosage form.

3. Greatest chemical and microbial stability over all oral dosage form.

DISADVANTAGES [57]

1. Some drugs resist compression into dense compacts, owing to amorphous nature, low density character.

2. Bitter tasting drugs, drugs with an objectionable dour or drugs that are sensitive to oxygen may require encapsulation or coating.

3. Difficult to swallow in case of children and unconscious patients.

4. Drugs with poor wetting, slow dissolution properties, optimum absorption high in GIT may be difficult to formulate or manufacture as a tablet that will still provide adequate or full drug bioavailability.

IDEAL CHARACTERSTICS OF BILAYER TABLETS [58]

1. A bi-layer tablet should have elegant product identity while free of defects like chips, cracks, and contamination.

2. It should have sufficient strength to with stand mechanical shock during its production packaging, shipping and dispensing.

3. It should have the chemical and physical stability to maintain its physical attributes over time. The bi-layer tablet must be able to release the medicinal agents in a predictable and reproducible manner.

4. It must have a chemical stability shelf-life, so as not to follow alteration of the medicinal agents.

Various Approaches to Bilayer Tablets

1. Floating drug delivery system These are manufactured for having lower density in order that they can float over gastric contents following that if they are being administered till the system breaks down. The two basic approaches to get floating dosages are Intra-gastric bilayer floating tablets, and multiple-unit type floating pills. Both of those are explained as given below.

2.Multiple unit types floating pills - These pills contain of expanded/sustained release as seeds encapsulated by double layers.

3. Swelling System These are manufactured to be considerably small on being administered for casing the dose ingestion. It leaves the stomach after its gradual erosion or breaking down to smaller hits.

Techniques of Bilayer Tablets

Various bilayer tablet techniques are employed to generate the desired quality of bilayer tablets. The techniques involved in this process include osmotic-release oral system (OROS) push-pull technology. These are explained as below with diagrams.

1.OROS Push-pull technology

This technology mostly includes two or three layers, among which the primary one or two layers contain the active pharmaceutical ingredient and therefore the last one is the push layer.



Fig.1.4. OROS Push-pull technology

2. L-OROS Tm Technology

This technology is formed by Alza and solves a serious problem of solubility. It had been then covered by a barrier membrane, followed by the osmotic push layer, and then, the semipermeable membrane was punctured for an exit cavity.



Fig.1.5: L-OROS Tm technology

3. DUROS Technology (Alza corporation)

The Duros technology relies on the implant technique and acts as a substitute for the transmission of numerous therapeutic substances, the therapeutic compounds are protected due to these cylinders, hence, making it resistant to human tissues for a long period (Fig. 10). For the annual palliative treatment of advanced prostate cancer, Viadur this technology is employed.



Fig.1.6: DUROS Technology

4. Elan Drug Technologies' Dual Release Drug Delivery System (DUREDAS technology)

Dual drug delivery system (DUREDAS) is a technology employed by Elan corporations technology for two distinct discharge amounts or double discharge from a solo dosage. This generates a posh controlled-hydrophilic matrix that is still compact and gradually absorbs liquid from the alimentary canal (GI tract). This technology offers a combined release pattern of drugs, or in simple words, sustained or immediate release.



Fig.1.7: EN SO TROL technology

5. Geminex Technology

This technology helps massively in increasing the therapeutic effectiveness of the drugs while also minimizes their side effects. It is extremely beneficial for patients as well as the industry and is largely used by pen west in for cardiovascular diseases, CNS disorders, diabetes, cancer, and central nervous system (CNS) disorders.

6. Programmable Oral Drug Absorption System (PRODAS)

PRODAS, also known as multi particulate drug technology (Elan Corporation). encapsulates mini-tablets of controlled drug release, with size ranging from 1.5 to 4 mm. used for providing the combined benefits of these drugs in one dose.

7. Geomatrix Technologies

Geomatrix technology generates a multilayer tablet, wherein an active ingredient is present inside a matrix core surrounded by one or more modulating layers (acting as a barrier) bonded to the central matrix in the course of the tablet generating process.

1.5.6 Types of Bi-Layered Tablet Press

1. Single sided tablet press.

2. Double sided tablet press.

3. Bi-layered tablet press with displacement monitoring

1.Single Sided Tablet Press: the only design may be a single sided press with both chambers of the doublet feeder separated from one another. Each chamber is gravity or forced fed with different power, producing the two individual layers of tablets.

Double Sided Tablet Press: In most double sided tablet presses with automated production control use compression force to watch and control tablet weight. The effective peak compression force exerted on each individual tablet of layer is measured by the system at main compression of the layer. [58]

Bi-layered Tablet Press with Displacement Monitoring: The displacement tablet weight control principle is fundamentally different from the principle based upon compression force. When measuring displacement, the control system sensitivity does not depend on the tablet weight but depends on the applied pre-compression force.

CONCLUSION:

Bi-layer tablets prescribe a great chance for producers to isolate themselves from their rivals, work on their items' viability, and safeguard against mirror items.

Bi-layer tablet quality and GMP prerequisites can change generally. This makes sense of

why various kinds of presses are being utilized to deliver bi-layer tablets, going from

basic single-sided presses to exceptionally modern machines. At the point when a quality bi-layer tablet.

should be created related to precise weight control of the two layers, pressure

force-controlled presses are obviously restricted due to their inadequate awareness and subsequently absence of exactness at low pressure powers expected to get interlayer holding. Such issues become much more evident when the tableting speed is high or expanded. Exact

individual layer weight checking/control at high velocity and in blend with decreased layer partition chance can be accomplished with the dislodging weight control framework based

presses.

REFERENCES:

1. Rajaei E, Jalali SMS, HLAs in Autoimmune Diseases: Dependable Diagnostic Biomarkers? Current rheumatology reviews. 2019

2. Klein BE, Klein R, Moss SE, Cruickshanks KJ, Parental history of diabetes in a population-based study. Diabetes care. 1996 Aug

3. Barnett AH, Eff C, Leslie RD, Pyke DA, Diabetes in identical twins. A study of 200 pairs. Diabetologia. 1981 Feb

4. Saxena R, Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (New York, N.Y.). 2007 Jun 1

5. Sladek R, Rocheleau G, Vincent D, A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007 Feb 22

6. Yasuda K, Miyake K, Horikawa Y, Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nature genetics. 2008 Sep

7. Zeggini E, R, Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature genetics. 2008 May

8. Fajans SS, Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. The New England journal of medicine. 2001 Sep 27

9. Shields BM, Hicks S, Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010 Dec

10. Kühl C, Etiology and pathogenesis of gestational diabetes. Diabetes care. 1998 Aug

11. Umpierre D, HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011 May 4

12.Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group., 2002 Feb 7

13. de Boer IH, Bangalore S, Zoungas S, Bakris G, Diabetes and Hypertension: A Position Statement by merican Diabetes Association. Diabetes care. 2017 Sep

14. Holman RR, Paul SK, Bethel MA, follow-up of intensive glucose control in type 2 diabetes. The New England journal of medicine. 2008 Oct 9

15. "High Blood Pressure Fact Sheet". CDC. 19 February 2015. Archived from the original on 6 March 2016. Retrieved 6 March 2016.

16. Lackland DT, Weber MA (May 2015). "Global burden of cardiovascular disease and stroke: hypertension at the core". The Canadian Journal of Cardiology.

17. Mendis S, Norrving B (2011). World Health Organization and the World Stroke Organization. p. 38. ISBN 9789241564373. Archived (PDF) from the original on 17 August 2014.

18. Hernandorena I, Duron E, Vidal JS, Hanon O (July 2017).Expert Opinion on Pharmacotherapy

19. Poulter NR, Prabhakaran D, Caulfield M (August 2015). "Hypertension". Lancet. 386 (9995): 801–812.

20. Carretero OA, Oparil S (January 2000). "Essential hypertension. Part I: definition and etiology". Circulation.

21. Yang, Bo-Yi (2018). "Global association between ambient air pollution and blood pressure: A systematic review and meta-analysis". Environmental Pollution.

22. Whelton PK, Carey RM, Aronow WS, Wright JT (June 2018). "2017

23. "How Is High Blood Pressure Treated?". National Heart, Lung, and Blood Institute. 10 September 2015. Archived from the original on 6 April 2016. Retrieved 6 March 2016.

24. Campbell NR, Lackland DT, prevention and control of hypertension and reduction in dietary salt. Journal of Clinical Hypertension.

25. Jump up to:[a] [b] Lau DH, Nattel S, (August 2017). "Modifiable Risk Factors and Atrial Fibrillation". Circulation (Review).

26. "Hypertension". www.who.int. Retrieved 13 May 2022.

27. Mancia G, Fagard R, Narkiewicz K, (July 2013).

28. James PA, Oparil S, Carter BL, Cushman WC, Ortiz E (February 2014).

29. Musini VM, Tejani AM, Bassett K, Puil L, Wright JM (June 2019). "Pharmacotherapy for hypertension in adults 60 years or older". The Cochrane Database of Systematic Reviews

30. Sundström J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B (February 2015).

31. Xie X, Atkins E, Lv J, Bennett A, Rodgers A (January 2016). 435–443.

32. Diao D, Wright JM, Cundiff DK, Gueyffier F (August 2012). The Cochrane Database of Systematic Reviews. 2017 (8)

34. Musini VM, Gueyffier F, Wright JM (August 2017). "Pharmacotherapy for hypertension in adults aged 18 to 59 years". The Cochrane Database of Systematic Reviews. 2017 (8):

35. Chobanian AV, Bakris GL, Black HR. (Joint National Committee On Prevention, National High Blood Pressure Education Program Coordinating Committee) (December 2003).

36.Conway J (April 1984). "Hemodynamic aspects of essential hypertension in humans". sPhysiological Reviews. 64 (2): 617–660.

37. Palatini P, Julius S (June 2009). "The role of cardiac autonomic function in hypertension and cardiovascular disease". Current Hypertension Reports. 11

38. Andersson OK, Lingman M, Himmelmann A (2004). "Prediction of future hypertension by casual blood pressure or invasive hemodynamics? A 30-year follow-up study". Blood Pressure. 13 (6): 350–354.

39. Folkow B (April 1982). "Physiological aspects of primary hypertension". Physiological Reviews. 62 (2): 347–504.

40. Struijker Boudier HA, le Noble JL, Messing MW, Huijberts MS, le Noble FA, van Essen H (December 1992). "The microcirculation and hypertension". Journal of Hypertension Supplement. 10 (7):

41. (February 1992). Hypertension. 19 (2 Suppl): II1-9. doi:10.1161/01.HYP.19.2_Suppl.II1-a. PMID 1735561.

42. Safar ME, London GM (August 1987). "Arterial and venous compliance in sustained hypertension". Hypertension. 10 (2):133–139. doi:10.1161/01.HYP.10.2.133. PMID 3301662

43. Navar LG (December 2010)."Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension". Journal of Applied Physiology. 109 (6): 1998–2000, discussion 2015.

44.Esler M, Lambert E, Schlaich M (December 2010). "Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension". Journal of Applied Physiology. 109 (6

45. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S (June 2009). "Endothelium-dependent contractions and endothelial dysfunction in human hypertension". British Journal of Pharmacology. 157 (4).

46. Marchesi C, Paradis P, Schiffrin EL (July 2008). "Role of the renin-angiotensin system in vascular inflammation". Trends in Pharmacological Sciences. 29 (7): 367–374.

47. Gooch JL, Sharma AC (September 2014). "Targeting the immune system to treat hypertension: where are we?". Current Opinion in Nephrology and Hypertension. 23 (5): 473–479.

48. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Wesley DJ (2011). 259–352.

49. "Hypertension in adults: diagnosis and management | Guidance and guidelines | NICE". www.nice.org.uk. Archived from the original on 9 April 2017. Retrieved 11 November 2018.

50. Whelton PK, He J, (October 2002). "Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program". JAMA. 288 (15): 1882–1888.

51. "Evidence-based policy for salt reduction is needed". Lancet. 388 (10043): 438. July 2016.

52. Esunge PM (October 1991). "From blood pressure to hypertension: the history of research". Journal of the Royal Society of Medicine.

53. Dustan HP, Roccella EJ, Garrison HH (September 1996). "Controlling hypertension. A research success story". Archives of Internal Medicine. 156 (17): 1926–1935.

54. Novello FC, Sprague JM (1957). "Benzothiadiazine dioxides as novel diuretics". J. Am. Chem. Soc.

55. Kahn SE: The relative contributions of insulin resistance and B-cell dysfunction to pathophysiology of Type 2 diabetes Diabetologia 46. Nature 402(6764), 880-883 (1999).

56. Chen M, Bergman RN, Pacini G, J. Clin. Endocrinol Metab.60(1), 13-20 (1985).

57. Pigeon RL, Kahn SE, Porte D Jr: Changes in insulin sensitivity, glucose effectiveness. and B-cell function in regularly exercising subjects. Metabolism 44(10), 1259-1263 (1995).